AccessHealth MA
Formerly known as Community Research Initiative (CRI)

Web Summary

Title:
A Phase 2 Randomized, Open-Label, Active-Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of Islatravir in Combination with Lenacapavir in Virologically Suppressed People With HIV.

Objective:
The objective of this multi-site study is to evaluate the safety and antiviral effect of an **oral weekly** regimen of islatravir in combination with lenacapavir.

Eligibility:
To be eligible to participate in the study, individuals must be 18 years of older with a suppressed viral load on Biktarvy.

Description:
Participants will be randomly allocated in a 2:1 ratio to receive **oral weekly** islatravir and lenacapavir or **oral daily** Biktarvy. Participants will receive study drugs for 48 weeks.

Following completion of the Week 48 visit, participants on daily oral Biktarvy will be given the option to change to the **oral weekly regimen** of islatravir and lenacapavir.

Study Sponsor: Gilead Sciences

For further information, please visit:
https://clinicaltrials.gov/ct2/show/NCT05052996

Or

For more information, please contact: Our Research Team, 617.502.1707 or info@accesshealthma.org

***Please note this Clinical Trial and Summary was started while AccessHealth MA was still known as Community Research Initiative (CRI). This information is still relevant.**